SERENA-6：动态ctDNA评估和精准癌症医学的未来

IF 82.2 1区医学 Q1 ONCOLOGY

Nature Reviews Clinical Oncology Pub Date : 2025-08-07 DOI:10.1038/s41571-025-01066-2

Arielle J. Medford, Seth A. Wander

{"title":"SERENA-6：动态ctDNA评估和精准癌症医学的未来","authors":"Arielle J. Medford, Seth A. Wander","doi":"10.1038/s41571-025-01066-2","DOIUrl":null,"url":null,"abstract":"The SERENA-6 trial assessed a paradigm-shifting approach to personalized cancer therapy in patients with advanced-stage breast cancer, in which therapy was switched upon the identification of resistance-related mutations in ESR1 in circulating tumour DNA (ctDNA). Herein, we discuss how the results of this trial challenge the standard-of-care management for these patients, in whom therapy changes are otherwise undertaken only after radiographic and/or clinical progression.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"115 1","pages":""},"PeriodicalIF":82.2000,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"SERENA-6: dynamic ctDNA assessment and the future of precision cancer medicine\",\"authors\":\"Arielle J. Medford, Seth A. Wander\",\"doi\":\"10.1038/s41571-025-01066-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The SERENA-6 trial assessed a paradigm-shifting approach to personalized cancer therapy in patients with advanced-stage breast cancer, in which therapy was switched upon the identification of resistance-related mutations in ESR1 in circulating tumour DNA (ctDNA). Herein, we discuss how the results of this trial challenge the standard-of-care management for these patients, in whom therapy changes are otherwise undertaken only after radiographic and/or clinical progression.\",\"PeriodicalId\":19079,\"journal\":{\"name\":\"Nature Reviews Clinical Oncology\",\"volume\":\"115 1\",\"pages\":\"\"},\"PeriodicalIF\":82.2000,\"publicationDate\":\"2025-08-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Reviews Clinical Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41571-025-01066-2\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41571-025-01066-2","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

SERENA-6试验评估了晚期乳腺癌患者个性化癌症治疗的范式转变方法，在循环肿瘤DNA （ctDNA）中ESR1的耐药相关突变鉴定后切换治疗。在此，我们讨论了该试验的结果如何挑战了这些患者的标准护理管理，在这些患者中，只有在放射学和/或临床进展后才进行治疗改变。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

SERENA-6: dynamic ctDNA assessment and the future of precision cancer medicine

The SERENA-6 trial assessed a paradigm-shifting approach to personalized cancer therapy in patients with advanced-stage breast cancer, in which therapy was switched upon the identification of resistance-related mutations in ESR1 in circulating tumour DNA (ctDNA). Herein, we discuss how the results of this trial challenge the standard-of-care management for these patients, in whom therapy changes are otherwise undertaken only after radiographic and/or clinical progression.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature Reviews Clinical Oncology 医学-肿瘤学

CiteScore

99.40

自引率

0.40%

发文量

114

审稿时长

6-12 weeks

期刊介绍： Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.